Dashboard
1
Poor Management Efficiency with a low ROCE of 7.28%
- The company has been able to generate a Return on Capital Employed (avg) of 7.28% signifying low profitability per unit of total capital (equity and debt)
2
High Debt Company with a Debt to Equity ratio (avg) at times
3
With a fall in Net Sales of -13.95%, the company declared Very Negative results in Mar 25
4
Risky -
Stock DNA
Pharmaceuticals & Biotechnology
CNY 635 Million (Micro Cap)
8.00
NA
0.00%
-0.49
3.56%
0.29
Revenue and Profits:
Net Sales:
104 Million
(Quarterly Results - Jun 2025)
Net Profit:
18 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
7.06%
0%
7.06%
6 Months
-0.64%
0%
-0.64%
1 Year
28.59%
0%
28.59%
2 Years
-21.07%
0%
-21.07%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Jiangsu Canopus Wisdom Medical Technology Co., Ltd. for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
-3.60%
EBIT Growth (5y)
-13.48%
EBIT to Interest (avg)
78.20
Debt to EBITDA (avg)
0
Net Debt to Equity (avg)
-0.49
Sales to Capital Employed (avg)
0.19
Tax Ratio
15.74%
Dividend Payout Ratio
61.22%
Pledged Shares
0
Institutional Holding
0
ROCE (avg)
7.28%
ROE (avg)
4.24%
Valuation key factors
Factor
Value
P/E Ratio
8
Industry P/E
Price to Book Value
0.29
EV to EBIT
-7.28
EV to EBITDA
-4.34
EV to Capital Employed
-0.41
EV to Sales
-1.14
PEG Ratio
NA
Dividend Yield
NA
ROCE (Latest)
Negative Capital Employed
ROE (Latest)
3.56%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Mildly Bearish
Mildly Bullish
RSI
No Signal
No Signal
Bollinger Bands
Bearish
Mildly Bullish
Moving Averages
Mildly Bullish (Daily)
KST
Bearish
Dow Theory
Mildly Bearish
No Trend
OBV
No Trend
No Trend
Shareholding Snapshot
No data for shareholding present.
Shareholding Compare (%holding) 
No data for shareholding present.
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
103.70
120.50
-13.94%
Operating Profit (PBDIT) excl Other Income
25.10
30.80
-18.51%
Interest
0.30
0.10
200.00%
Exceptional Items
2.60
0.50
420.00%
Consolidate Net Profit
18.00
27.90
-35.48%
Operating Profit Margin (Excl OI)
140.00%
166.70%
-2.67%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is -13.94% vs 3.17% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -35.48% vs -16.22% in Jun 2024
Annual Results Snapshot (Consolidated) - Dec'24
Dec'24
Dec'23
Change(%)
Net Sales
430.30
429.60
0.16%
Operating Profit (PBDIT) excl Other Income
118.10
111.80
5.64%
Interest
0.40
0.10
300.00%
Exceptional Items
-7.00
13.70
-151.09%
Consolidate Net Profit
96.90
99.90
-3.00%
Operating Profit Margin (Excl OI)
174.70%
167.00%
0.77%
USD in Million.
Net Sales
YoY Growth in year ended Dec 2024 is 0.16% vs -1.85% in Dec 2023
Consolidated Net Profit
YoY Growth in year ended Dec 2024 is -3.00% vs -3.66% in Dec 2023
About Jiangsu Canopus Wisdom Medical Technology Co., Ltd. 
Jiangsu Canopus Wisdom Medical Technology Co., Ltd.
Pharmaceuticals & Biotechnology
No Details Available.
Company Coordinates 
No Company Details Available






